Would Hydroxychloroquine Be A New Promising Drug in Managing Antiphospholipid Syndrome?

Amani Mohsen* and Rabih Chahine

1Obstetrics & gynecology consultant, Palestinian Red Crescent Society, Shatila Camp, Beirut, Lebanon
2Chairman of obstetrics & gynecology department, Rafik Hariri university Hospital, Beirut, Lebanon

Received: October 10, 2018; Published: October 15, 2018

*Corresponding author: Amani Mohsen, Obstetrics & gynecology consultant, Palestinian Red Crescent Society, Shatila Camp, Beirut, Lebanon

Abstract

Once Antiphospholipid syndrome (APS) is diagnosed, risk profile of the patient will impact its management whether there was a previous thrombotic event or not, association with other autoimmune disorders, presence of other obstetrical complications as well as being currently pregnant. The current recommended regimen for preventing obstetrical complications includes low molecular weight Heparin and low dose aspirin. This regimen decreases the risk of miscarriage by only 54%. Here, we will review the studies that evaluated adding Hydroxychloroquine (HCQ) to the treatment of APS and how effective it would be.

Keywords: Antiphospholipid syndrome; Hydroxychloroquine; Miscarriage

Introduction

Antiphospholipid syndrome is an autoimmune disorder defined by the presence of either vascular thrombosis or characteristic obstetrical morbidities along with positive laboratory tests of circulating antibodies. Women with APS would present with pregnancy morbidities including three recurrent miscarriages before 10th week or unexplained stillbirth [1]. Once diagnosis is confirmed, management of APS is warranted to prevent obstetrical morbidities and risk of thrombosis which would reach 25% during pregnancy and the postpartum period. Long term follow-up revealed that 50% of women with APS but without thrombotic events would develop vascular thrombosis during 3-10 years and 10% would develop systemic lupus erythematosus (SLE) [2]. Different guidelines recommend prophylactic heparin during pregnancy and the postpartum period to prevent risk of thrombosis and increase the rate of live births [1, 3]. In a Cochrane review of randomized trials, combination of low dose aspirin and heparin decreases the risk of miscarriage by 54% [4]. Without any pharmacologic treatment, the live birth rate would reach only 10% in women suffering from APS with recurrent miscarriage [5].

Looking for other medications that would decrease risk of thrombosis, Hydroxychloroquine (HCQ) was historically evaluated to play this role. HCQ is an anti-malarial medication which is used to treat autoimmune rheumatic conditions gaining benefit from its ability to boost immune system against self-antigens [6]. In 1970s, placebo controlled randomized trials examined HCQ as a promising agent to prevent postoperative venous thrombosis in fields of general and orthopedic surgeries, but it failed [7,8]. Later, in a nested case control study of SLE patients with thrombosis matched with SLE controls without thrombosis, HCQ was associated with 68% decrease in risk of thrombosis [9]. This reduction was only borderline (P=0.05) in a case control study of SLE patients with positive APS but without previous thrombosis matched with SLE controls without APS [10]. In a small prospective cohort study of primary APS with previous venous thrombosis, HCQ was added to the oral anticoagulant (OA) in 20 patients while the other 20 patients were treated with OA alone. Six cases of recurrences were documented in the group treated with OA alone versus no recurrence in the group treated with HCQ with OA. However, evidence from this study is limited due to small size of the cohort and selection bias where risk of relapses (30%) is also high in the group receiving OA [11].

Mekinian et al. [12] addressed the role of HCQ in pregnant women with APS without baseline SLE in a retrospective cohort study, where both cases and controls received combination treatment of low molecular weight heparin (LMWH) and aspirin with the addition of HCQ to the cases. Pregnancy loss was...


